非小细胞肺癌化学治疗与血清sAPO-1/Fas、NO的变化  

Chemotherapy of non small-cell lung cancer (NSCLC) and changes in serum sAPO-1/Fas and nitric oxide (NO) levels

作　　者：周建英[1] 朱旗[1] 姚杭平 陈水芳[1] 

机构地区：[1]浙江大学医学院附属第一医院呼吸内科,杭州310003 [2]浙江大学医学院传染病研究所

出　　处：《中华肿瘤杂志》2000年第3期225-227,共3页Chinese Journal of Oncology

摘　　要：目的　观察化疗药物替尼泊甙 (VM 2 6 )、表阿霉素 (EPI)、顺铂 (DDP)治疗非小细胞肺癌的疗效、毒性及治疗前后血清sAPO 1/Fas、NO含量的变化。方法　 42例诊断明确的晚期非小细胞肺癌 (NSCLC)患者 (鳞癌 2 8例 ,腺癌 12例 ,未分化癌 2例 )采用VM 2 6、EPI、DDP联合化疗 2个周期。化疗前后分别用双抗体夹心ELISA方法测定血清sAPO 1/Fas含量和用酶还原法测定血清NO含量。结果　化疗的总有效率 (完全缓解 +部分缓解 )为 47.6 % (2 0 /4 2 ) ,稳定 15例 ,进展 7例。有效组和鳞癌组治疗后血清sAPO 1/Fas水平较治疗前明显下降 (P <0 .0 5 )。鳞癌组、有效组和腺癌组血清NO水平较治疗前明显升高 (P <0 .0 5 )。结论　VM 2 6、EPI、DDP联合化疗对晚期NSCLC有较好的疗效。血清sAPO 1/Fas、NO水平可能反映细胞凋亡水平 。Objective To investigate the therapeutic efficacy, toxic side effects, and changes in serum level of sAPO 1/Fas and nitric oxide(NO) in NSCLC patients treated with VM 26, epirubicin (EPI) and cisplatin (VED regimen).Methods Forty two cases of advanced NSCLC patients (squamous cell carcinoma, 28; adenocarcinoma, 12; undifferentiated cancer, 2) were treated with 2 cycles of VED. Serum sAPO 1/Fas level was determined by ELISA method, and NO level by enzymatic method before and after treatment.Results The overall response rate was 47.6% (20/42). Serum sAPO 1/Fas level in patients with squamous cell carcinoma who responded to treatment was significantly lower than that before treatment. The post chemotherapy serum NO level was significantly higher than that before chemotherapy in responsive patients with squamous cell cancer as well as in adenocarcinoma.Conclusion Combination chemotherapy with VM 26, EPI and DDP can be useful in the treatment of patients with advanced NSCLC. Serum sAPO 1/Fas and NO levels could be used to monitor treatment effect.

关 键 词：肺肿瘤 药物疗法 非小细胞肺癌 替尼泊甙 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]